Johnson & Johnson Vision’s Acuvue Oasys Multifocal receives CE Mark
The latest addition to the Acuvue Oasys portfolio of products for patients with presbyopia is set to launch across Europe in 2021
The multifocal lens has already been approved in the US in 2020 by the Food and Drug Administration and is now set to launch in Europe this year.
Johnson & Johnson Vision suggested that the product represents an expansion of the Acuvue Oasys portfolio for patients with presbyopia.
The reusable lens features the Pupil Optimised Design technology that is currently available in the 1-Day Acuvue Moist Multifocal, making it available in both reusable and daily disposable modalities. The lens also follows the same fit process as the daily product.
The company suggested the Pupil Optimised Design provides “built-in personalisation for better visual performance.”
Sandra Rasche, area vice-president, Europe, Middle East and Africa, Vision Care for Johnson & Johnson Medical, explained: “Although there are 50 million presbyopia patients over the age of 45 across the EMEA region who are open to wearing contact lenses, fewer than 10% of this group are currently wearing a multifocal contact lens to correct the condition.”
“The Acuvue Oasys Multifocal with Pupil Optimised Design will offer an exciting solution for these patients, using a blend of technologies for better comfort and clearer vision at all distances,” Ms Rasche continued.
Johnson & Johnson Vision suggested the Acuvue Oasys Multifocal has a successful fit rate of 97.3% in two pairs of lenses or less.
For more on the multifocal market, take a look at OT’s February/March Supplier Insight feature, in which Johnson & Johnson Vision professional affairs manager, Ian Pyzer, describes prescribing trends and the introduction of Pupil Optimised Design.